Factor VIII

Factor VIII is another protein your body makes to help blood clot. It works with Factor IX to help activate Factor X, which is a crucial step in the clotting cascade. People with Factor VIII Deficiency have a higher risk of bleeding because their blood doesn't clot properly.

Brand names:Thromboplastinogen, Advate, Kogenate
Medication

What people taking Factor VIII report

Every report comes from a Lived member, sent anonymously.

Have you tried Factor VIII for Hemophilia A?

NameHow it went

About Factor VIII

What It's For

Factor VIII is a clotting protein the body needs to form a stable clot. People with hemophilia A are born with too little of it, or with a version that does not work properly, so they bleed longer after injuries, surgery or dental work and can bleed into joints and muscles without an obvious cause. Factor VIII concentrate, also called antihemophilic factor, is a medicine that supplies the missing protein. It is used to treat bleeds as they happen, to prevent bleeding around surgery and procedures, and as regular preventive treatment (prophylaxis) to reduce how often bleeds occur. Several products exist. Most are recombinant, meaning they are made in cell cultures rather than from donated blood; Advate is a widely used example, and Adynovate and Altuviiio are longer-lasting versions. Other products, such as Alphanate, are purified from human plasma and also contain von Willebrand factor, which lets some of them be used for certain people with von Willebrand disease, another inherited bleeding disorder. The recombinant products are not approved for von Willebrand disease. A separate product, Obizur, is used for acquired hemophilia A, a rare condition in which the immune system attacks a person's own factor VIII. Hemophilia B is caused by a lack of a different protein, factor IX, and is not treated with factor VIII.

How It Works

Clotting happens through a chain of proteins that switch each other on. Factor VIII acts as a helper in that chain: it speeds up a key step that produces thrombin, the enzyme that builds the fibrin mesh of a firm clot. Without enough factor VIII, a clot may start to form but is weak and slow, which is why bleeding in hemophilia tends to continue or restart rather than being faster at the outset. Infused factor VIII temporarily raises the level in the blood so clotting can work closer to normal. It does not fix the underlying genetic cause. The body clears it over hours to days, which is why preventive treatment has to be repeated on a schedule and why longer-lasting versions were developed.

Dosage & Administration

Factor VIII comes as a powder that is mixed with sterile liquid and injected into a vein. It can be given at a hemophilia treatment center, a clinic or at home. Many people, and parents of children with hemophilia, learn to do the infusions themselves, but only after being trained by the hemophilia team. Once mixed, the solution has to be used within a few hours. Doses are measured in international units and calculated from body weight, the factor level the team wants to reach and, for a bleed, how serious and where it is. A bleed into the head or abdomen needs a higher level for longer than an early joint bleed. For preventive treatment, standard products are often given every other day or three to four times a week, while some extended half-life products are given less often; Altuviiio, for example, is given once a week. Because people clear factor VIII at different rates, the team may check blood factor levels to adjust the plan. Each product has its own instructions, so one should not be swapped for another without the prescriber.

Side Effects

Most infusions cause no noticeable problems. Reported effects include headache, fever, cough, cold-like symptoms, joint pain, vomiting and diarrhea, and some people have mild discomfort where the needle goes in. Allergic reactions are uncommon but can be serious. Hives, itching, flushing, facial swelling, chest tightness, wheezing, trouble breathing, or feeling dizzy or faint during or after an infusion mean the infusion should be stopped. Swelling, trouble breathing or faintness can signal anaphylaxis, a severe whole-body allergic reaction: call 911.

Interactions & Warnings

The most important complication is the development of inhibitors. These are antibodies the immune system makes against infused factor VIII, and they can make treatment much less effective or stop it working. They develop most often in people who have had little or no previous treatment, especially children who are just starting treatment, and the care team checks for them with blood tests. If a bleed is not controlled by the usual dose, or bleeds seem to be getting more frequent despite treatment, contact the hemophilia treatment center promptly, since this can be a sign of an inhibitor. Inhibitors change the treatment plan, often to other medicines. Advate and some other recombinant products are made in hamster cells and may contain trace mouse or hamster protein, so they should not be used by people who have had a life-threatening allergic reaction to those proteins or other ingredients. Plasma-derived products go through donor screening, testing and virus inactivation or removal steps, but because they come from human blood they carry a small theoretical risk of transmitting infections. Plasma-derived products that also contain von Willebrand factor have been linked to blood clots, mainly in people with von Willebrand disease who have other clot risk factors.

What to Expect

A treated bleed usually settles over one to a few days, with repeat doses as the team directs; serious bleeds can need treatment for longer, often in hospital. Many care plans include keeping factor at home so a bleed can be treated as soon as it is recognized, without waiting for a clinic visit. For people with severe hemophilia A, regular preventive infusions are the usual approach. Clinical trials comparing them with treating bleeds only when they happen found far fewer joint bleeds and better joint health and pain scores over time, though not everyone becomes bleed-free and repeated bleeds into a joint can still cause damage. Routine visits at a hemophilia treatment center review bleed records, joint health and inhibitor testing. Travel takes planning, including bringing enough factor for the trip. Factor VIII is one of several options. Emicizumab (Hemlibra) is an antibody that does part of factor VIII's job in the clotting chain. It is injected under the skin rather than into a vein and is approved for preventing bleeds in hemophilia A, with or without inhibitors. It is used for prevention only, so bleeds that still happen and surgery are managed with other treatments, which can include factor VIII. The choice between them depends on age, venous access, inhibitor status, how active a person is and personal preference.

Questions to Ask Your Doctor

  1. 1.Would regular preventive infusions or treating bleeds as they happen suit my situation better, and why?
  2. 2.Is a standard or an extended half-life product a better fit for my schedule and activity level?
  3. 3.How do I recognize an early joint or muscle bleed, and what dose should I give at home?
  4. 4.How often will you test for inhibitors, and what would we do if one develops?
  5. 5.Should I consider emicizumab or another non-factor option, and when would I still need factor VIII?

Last reviewed • Oct 2026

Educational content, not medical advice.